CardiAMP is a cell therapy commercialized by BioCardia, with a leading Phase III program in Systolic Heart Failure. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CardiAMP’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for CardiAMP is expected to reach an annual total of $71 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CardiAMP Overview

CardiAMP is under development for the treatment of chronic myocardial ischemia with refractory angina, left ventricular dysfunction and ischemic systolic heart failure. The therapeutic candidate comprises of culture expanded, bone-marrow derived, autologous stem cells and is delivered trough helix/morph intramyocardial delivery catheter system.

BioCardia Overview

BioCardia is a regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidates that include a CardiAMP cell therapy system, autologous minimally processed bone marrow cells and an allogeneic off-the-shelf mesenchymal stem a cell product candidate for ischemic systolic heart failure. BioCardia‘s CardiAMP cell therapy system comprises a cell potency screening test, a point-of-care cell processing platform, and a biotherapeutic delivery system. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US

The company reported revenues of (US Dollars) US$1.4 million for the fiscal year ended December 2022 (FY2022), an increase of 33.2% over FY2021. The operating loss of the company was US$11.9 million in FY2022, compared to an operating loss of US$12.6 million in FY2021. The net loss of the company was US$11.9 million in FY2022, compared to a net loss of US$12.6 million in FY2021. The company reported revenues of US$0.1 million for the first quarter ended March 2023, a decrease of 39.6% over the previous quarter.

For a complete picture of CardiAMP’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.